Techniques and material used in the percutaneous treatment of chronic coronary occlusions. Data from the CIBELES study

Raul Moreno\textsuperscript{a,*}, Eulogio García\textsuperscript{b}, Rui Teles\textsuperscript{c}, Jose-Ramon Rumoroso\textsuperscript{d}, Henrique Cyrne Carvalho\textsuperscript{e}, Francisco Javier Goicolea\textsuperscript{f}, José Moreu\textsuperscript{g}, Fina Mauri\textsuperscript{h}, Manel Sabaté\textsuperscript{i}, Vicente Mainar\textsuperscript{j}, Lino Patricio\textsuperscript{k}, Mariano Valdés\textsuperscript{l}, Carlos Cuellas\textsuperscript{m}, Manuel Almeida\textsuperscript{c}, Angel Sánchez-Recalede\textsuperscript{a}, Guillermo Galeote\textsuperscript{a}, Santiago Jimenez-Valero\textsuperscript{a}, Luis Calvo\textsuperscript{a}, Ignacio Plaza\textsuperscript{a}, Jose-Luis Lopez-Sendón\textsuperscript{a}, Jose-Luis R. Martín\textsuperscript{n}, on behalf of the investigators of the CIBELES trial\textsuperscript{1}

\textsuperscript{a} Interventional cardiology, University Hospital La Paz, Madrid, Spain
\textsuperscript{b} Interventional cardiology, Hospital Clínico, Madrid, Spain
\textsuperscript{c} Interventional cardiology, Hospital de Santa Cruz, Lisbon, Portugal
\textsuperscript{d} Interventional cardiology, Hospital de Galdakao, Bilbao, Spain
\textsuperscript{e} Interventional cardiology, Hospital de Santo António, Porto, Portugal
\textsuperscript{f} Interventional cardiology, Hospital Puerta de Hierro, Majadahonda, Spain
\textsuperscript{g} Interventional cardiology, Hospital Virgen de la Salud, Toledo, Spain
\textsuperscript{h} Interventional cardiology, Hospital German Trias i Pujol, Badalona, Spain
\textsuperscript{i} Interventional cardiology, Hospital Santa Creu i Sant Pau, Barcelona, Spain
\textsuperscript{j} Interventional cardiology, Hospital General, Alicante, Spain
\textsuperscript{k} Interventional cardiology, Hospital de Santa Marta, Lisbon, Portugal
\textsuperscript{l} Interventional cardiology, Hospital Virgen de la Arrixaca, Murcia, Spain
\textsuperscript{m} Interventional cardiology, Complejo Hospitalario, León, Spain
\textsuperscript{n} Interventional cardiology, School of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain

Received 3 October 2012; accepted 1 November 2012
Available online 27 July 2013

KEYWORDS
Coronary stents; Coronary angioplasty; Chronic occlusion; Coronary artery disease

Abstract
Introduction: In recent years, various specific techniques and materials have been developed for the treatment of coronary chronic total occlusions (CTO).
Objective: To evaluate the current situation in the treatment of CTO (techniques and material) in our setting.
Methods: We evaluated data on techniques and material used in the CIBELES (Chronic coronary occlusion treated by Everolimus Eluting Stent) trial, a randomized comparison of sirolimus- and everolimus-eluting stents in 207 patients with CTO in 13 centers in Spain and Portugal.
Results: A radial approach was used in 23% of patients, and retrograde techniques were used in only 5%. A high number of balloons were used (2.2 ± 0.9 per patient). Microcatheters were...
used in 33% of patients, and post-dilatation balloons in only 25%. The mean number of stents implanted per patient was $2.1 \pm 1.0$, with a mean total stent length of $49 \pm 24$ mm. Other devices and techniques used were: Tornus penetration catheter in 4% of patients, rotational atherectomy in 2%, and cutting balloon in 1%. Intracoronary ultrasound was used in only 6% of patients. In 34% of cases, operators used guidewires that were not specifically for CTO. Considerable variability between centers was detected in the use of different techniques, the highest and lowest variability being observed in the use of intracoronary ultrasound and the use of CTO guidewires, respectively.

**Conclusions:** In the CIBELES trial, techniques and devices specifically designed for the treatment of CTO were used in a relatively low proportion of patients. Considerable variability between centers was detected.

© 2012 Sociedade Portuguesa de Cardiologia. Published by Elsevier España, S.L. All rights reserved.

---

**Introduction**

Coronary chronic total occlusions (CTO) still constitute one of the most difficult challenges for interventional cardiologists, due mainly to difficulty in achieving adequate vessel recanalization, but also to high rates of restenosis, reocclusion, and new revascularization procedures in cases with an initial successful result.¹⁻³ For these reasons, in recent years various specific devices and techniques have been developed and guidelines have been established for appropriate treatment of these lesions.⁴⁻⁶

Our objective was to assess the current situation regarding treatment of CTO in terms of devices and techniques used, based on the results of the CIBELES (Chronic coronary occlusion treated By Everolimus Eluting Stent) trial, a randomized comparison of sirolimus- and everolimus-eluting coronary stents in 207 patients with CTO.⁷⁻⁸

---

**Methods**

**Study population**

The CIBELES trial (Clinicaltrials.gov identifier NCT00793221) included 207 patients with a coronary CTO with an estimated duration of occlusion >2 weeks.⁷⁻⁸ The patients were randomly allocated to everolimus-eluting (Xience V, Abbott Vascular) or sirolimus-eluting (Cypher, Cordis, Johnson & Johnson) coronary stents. In the latest guidelines on the treatment of CTO, CTO was defined as a total occlusion with an estimated duration of occlusion >3 months. However, in the CIBELES study an estimated duration of occlusion >2 weeks was used, for two reasons. First, most studies comparing different strategies to reduce restenosis in CTO included patients with an estimated duration of occlusion >2 weeks. Second, in the CIBELES study, two different types
of drug-eluting stents were compared, taking late loss as the primary endpoint, and duration of occlusion has more impact on the probability of crossing the occlusion than on the risk of restenosis. Despite these two considerations, estimated duration of occlusion in the CIBELLES study was >3 months in 80% of cases. Other inclusion and exclusion criteria have been previously published.

Thirteen centers in Spain and Portugal participated in the study, all of them with a high volume of percutaneous coronary interventions on CTO. The Spanish Society of Cardiology sponsored the study, which was partly funded by an unrestricted grant from Abbott Vascular. The study was monitored by Chiltern International, and had an independent clinical events committee.

Data collection

For every patient, data were collected on approach (anterograde or retrograde, femoral or radial), material and techniques used (types of guidewires, balloons, microcatheters, intravascular ultrasound, rotational atherectomy, etc.), type of anticoagulation and amount of contrast. All these aspects were left to the operators’ discretion, respecting local practice, and hence the data obtained reflect standard practice in each center.

Statistical analysis

The statistical analysis was performed with SPSS version 12.0 (SPSS Inc., Chicago, IL, USA). Continuous variables are presented as mean ± standard deviation, and qualitative variables as proportions (percentages). Means were compared with the Student’s t test, and proportions were compared using the chi-square test (with Fisher’s correction when necessary). Differences were considered statistically significant with a p value <0.05.

In order to evaluate variability between different participating centers, the variation coefficient was calculated for different study variables (standard deviation/mean).

Results

Baseline characteristics of the study population (Tables 1 and 2)

The patients’ mean age was 64 ± 10 years, and 83% were male. About 36% of patients were diabetic. Due to the inclusion criteria, all treated lesions were de novo and located in native vessels. The treated vessel was the left anterior descending artery, right coronary artery, and left circumflex artery in 41%, 39%, and 19%, respectively.

Techniques and devices used (Table 3)

A radial approach was used in 23% of cases; a retrograde approach was used in only 5% of patients. The use of radial (0%-92%) and retrograde approaches (0%-18%) both showed considerable variability between participating centers (Figure 1).
Antithrombotic treatment

Antiplatelet therapy consisted of aspirin and clopidogrel in all patients. Additionally, 4% of patients received glycoprotein IIb/IIa inhibitors. Anticoagulation during the procedure was performed with unfractionated heparin in most cases (87%), followed by bivalirudin (12%) and enoxaparin (1%). In eight of the 13 centers (62%), unfractionated heparin was the only anticoagulation used.

Variability between participating centers

Figure 1 shows the variability between participating centers. The greatest variability was observed in the use of intracoronary ultrasound (variation coefficient 2.14), and the least was found in the use of guidewires specific for CTO (variation coefficient 0.37).

Comparison between patients with a duration of occlusion >3 months vs. <3 months

Table 4 shows the comparison between patients with an estimated duration of occlusion >3 months and <3 months. Of the 207 patients, 165 (80%) had an estimated duration of occlusion >3 months. These patients had higher rates of specific techniques for CTO (specific guidewires, microcatheters, etc.), but the differences were statistically significant only in the use of a radial approach (20% vs. 36%; p=0.031). A retrograde approach was used in 6% of patients with duration of occlusion >3 months, compared to 0% in patients with estimated duration of occlusion of between 2 weeks and 3 months. A trend for a higher rate of use of plaque modification devices (rotational atherectomy, cutting balloon, Tornus catheter) was found in patients with >3 months since occlusion (9% vs. 0%, p=0.078).
Techniques and material used in the percutaneous treatment

<table>
<thead>
<tr>
<th>Approach (%)</th>
<th>76.8</th>
<th>23.2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Femoral</td>
<td>Radial</td>
<td></td>
</tr>
<tr>
<td>Size of guiding catheter (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6 French</td>
<td>75.8</td>
<td>11.6</td>
</tr>
<tr>
<td>7 French</td>
<td>11.6</td>
<td></td>
</tr>
<tr>
<td>8 French</td>
<td>12.6</td>
<td></td>
</tr>
<tr>
<td>Retrograde approach (n/%)</td>
<td>4.8</td>
<td></td>
</tr>
<tr>
<td>Number of guidewires</td>
<td>2.0±1.2</td>
<td></td>
</tr>
<tr>
<td>Number of microcatheters</td>
<td>0.4±0.5</td>
<td></td>
</tr>
<tr>
<td>Number of balloons</td>
<td>2.2±0.9</td>
<td></td>
</tr>
<tr>
<td>Pre-dilatation</td>
<td>1.9±0.7</td>
<td></td>
</tr>
<tr>
<td>Post-dilatation</td>
<td>0.3±0.4</td>
<td></td>
</tr>
<tr>
<td>Number of stents</td>
<td>2.1±1.0</td>
<td></td>
</tr>
<tr>
<td>Total stent length (mm)</td>
<td>49±24</td>
<td></td>
</tr>
<tr>
<td>Maximum stent diameter (mm)</td>
<td>2.9±0.4</td>
<td></td>
</tr>
<tr>
<td>Minimum stent diameter (mm)</td>
<td>2.6±0.4</td>
<td></td>
</tr>
<tr>
<td>Intracoronary ultrasound (%)</td>
<td>5.8</td>
<td></td>
</tr>
<tr>
<td>Other techniques (%)</td>
<td>6.8</td>
<td></td>
</tr>
<tr>
<td>Rotational atherectomy</td>
<td>2.4</td>
<td></td>
</tr>
<tr>
<td>Cutting balloon</td>
<td>1.0</td>
<td></td>
</tr>
<tr>
<td>Tornus catheter</td>
<td>4.4</td>
<td></td>
</tr>
<tr>
<td>Amount of contrast dye (ml)</td>
<td>284±130</td>
<td></td>
</tr>
<tr>
<td>Antithrombotic treatment (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unfractionated heparin</td>
<td>86.5</td>
<td></td>
</tr>
<tr>
<td>Bivalirudin</td>
<td>12.1</td>
<td></td>
</tr>
<tr>
<td>Enoxaparin</td>
<td>1.4</td>
<td></td>
</tr>
<tr>
<td>Glycoprotein IIb/IIIa blockers</td>
<td>3.9</td>
<td></td>
</tr>
</tbody>
</table>

Discussion

Among patients undergoing coronary angiography, 13-18% have one or more CTO.\(^7,10\) Treatment of CTO constitutes one of the most complex tasks for interventional cardiologists, due mainly to difficulty in recanalizing the vessel, but also to the high risk of restenosis, reocclusion and new revascularization procedures in patients with an initial successful result.\(^1,7\) This explains why only about 10% of CTO are scheduled for percutaneous revascularization, and most cases are managed either with medical treatment alone or with surgical revascularization.\(^7,10\)

Several studies have shown that successful treatment of CTO is associated with improvement in left ventricular ejection fraction and clinical outcomes.\(^3,11\) Thus, in spite of the technical difficulties associated with percutaneous treatment of this type of lesion, CTO is currently one of the fields of greatest interest for interventional cardiologists, and consequently a wide variety of devices, recommendations, and techniques have been developed specifically to treat these lesions. As a result, the variability between different centers in the treatment of CTO is greater than with other types of lesions, and therefore data obtained from a single center are difficult to apply to other centers.

The CIBELES trial was performed in 13 centers in Spain and Portugal, in which 207 patients with CTO were managed either with medical treatment alone or with surgical revascularization.\(^7\)
These data suggest that recommendations by CTO expert groups may not be applicable to CTO.

Second, the total stent length was high (nearly 50 mm). In some previous randomized studies of patients with CTO, total stent length was less, probably reflecting patient selection. However, other studies showed a similarly high stent length to CIBELES, which probably reflects the fact that CTO are frequently associated with long-segment disease.

Third, a relatively high proportion of patients did not receive any device, material or technique developed specifically for the treatment of CTO. For example, retrograde techniques were used in only 5% of patients, demonstrating that they have a low penetration in daily practice in Spain and Portugal. In some CTO registries, mainly Japanese, this percentage is around 25%. The use of devices recommended by CTO expert groups was also relatively low. Microcatheters were used in one third of patients, 34% of patients did not require specific guidewires, and the procedure was guided by intracoronary ultrasound in only 6% (Table 5). In patients with >3 months since vessel occlusion, the use of these devices was slightly more frequent, but also less than expected. On the other hand, the use of a radial approach (frequently not recommended in CTO because it provides less support than a femoral approach) was relatively high (23%), even in patients with duration of occlusion >3 months. These data suggest that recommendations by CTO expert groups may not be applicable to the routine treatment of these lesions. However, this does not necessarily imply suboptimal use of resources, but perhaps that the recommendations of these expert groups are unrealistic. All physicians participating in the CIBELES trial were experienced interventional cardiologists with wide experience in the treatment of CTO.

Four, post-dilatation balloons were used in only 25% of patients. This could be considered a low figure, given the expected high proportion of underexpanded and/or malapposed stents in such long stented segments.

Five, other issues, such as the use of other techniques (e.g. rotational atherectomy), antithrombotic treatment, and the amount of contrast dye, were consistent with other CTO series.

Finally, due to its study design, all patients included in the CIBELES trial received drug-eluting stents. Recent recommendations on the treatment of CTO do not clearly indicate the routine use of drug-eluting stents in these lesions, but we believe that, unless there is an absolute contraindication for prolonged double antiplatelet therapy, all CTO should be treated with drug-eluting stents, particularly with sirolimus- or everolimus-eluting stents. In fact, the use of drug-eluting stents was >95% in some recent registries on CTO.

Study limitations

This study has some limitations. First, the main objective of the CIBELES trial was to compare two different types of drug-eluting stents, and did not include analysis of the material and techniques used in the trial’s endpoints. However, this in fact reinforces the findings related to the techniques and material used: since no specific recommendations were given in the study, the data in this article reflect the daily practice of the participating centers. Second, due to the study design, in all included patients the guidewire successfully crossed the vessel occlusion, and this may have influenced the study’s results. However, we believe this may be only applicable to guidewires, and not to other devices used in CTO. Third, the centers participating in the CIBELES trial were only in Spain and Portugal, and treatment of CTO may differ in other countries. Despite these limitations, we believe that the findings probably reflect daily practice in most countries and centers treating CTO, at least in Europe and the USA.

Ethical disclosures

Protection of human and animal subjects. The authors declare that the procedures followed were in accordance with the regulations of the relevant clinical research ethics committee and with those of the Code of Ethics of the World Medical Association (Declaration of Helsinki).

Confidentiality of data. The authors declare that they have followed the protocols of their work center on the publication of patient data and that all the patients included in the study received sufficient information and gave their written informed consent to participate in the study.

Right to privacy and informed consent. The authors have obtained the written informed consent of the patients or subjects mentioned in the article. The corresponding author is in possession of this document.

Funding

Unrestricted grant from Abbott Vascular.

Conflicts of interest

The authors have no conflicts of interest to declare.

Annex. (LIST OF INVESTIGATORS)


References


